PRE-SURVEY: ANTI-CD38 THERAPIES IN MULTIPLE MYELOMA

Advisory Board on Isatuximab Subcutaneous (Isa SC) OBI

This pre-survey is designed to gather insights from Advisory Board members regarding current clinical experiences with anti-CD38 therapies in multiple myeloma (MM), including preparation requirements, patient management protocols, and perspectives on home administration. Your responses will help guide our Advisory Board discussion and ensure we address the most relevant topics for clinical practice.

Instructions for completion

• Please complete all sections to the best of your ability based on your clinical experience.
• For ranking questions, assign numbers in order of significance (1 = most significant/important).
• For multiple choice questions, select all options that apply where indicated.
• Open-ended questions provide space for detailed responses; please be as specific as possible.
• All responses will be kept confidential and used solely for Advisory Board preparation purposes.

Estimated completion time: 30–35 minutes

sanofi